NEW YORK GENOME CENTER INC: Form 990, tax year 2024
View the entire original 990 at ProPublica ↗
- Organization
- NEW YORK GENOME CENTER INC (EIN 80-0631734)
- Tax period
- 2024-01-01 to 2024-12-31
- Filed
- 2025-11-05
- IRS object ID
- 202533099349302893
- Schema version
- 2024v5.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule L
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2025-11-05T13:59:01-06:00 | ReturnTs |
| Tax Period End | 2024-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 135565207 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | TWO MANHATTAN WEST 375 9TH AVENUE | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10001 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2024-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 800631734 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | NEW YORK GENOME CENTER INC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | NEWY | BusinessNameControlTxt |
| Phone | 6469777000 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 AVENUE OF THE AMERICAS 7TH FL | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 100131941 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | NANCY KONG | PersonNm |
| Person Title | INTERIM CFO | PersonTitleTxt |
| Phone | 6469777000 | PhoneNum |
| Signature | 2025-10-31 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | 0 | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | EVAN W SEEKAMP | PreparerPersonNm |
| PTIN | P01907071 | PTIN |
| Phone | 2127589700 | PhoneNum |
| Preparation | 2025-10-31 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2024 | TaxYr |
| Build TS | 2025-03-06 01:10:19Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | TOM MANIATIS | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 AVE OF THE AMERICAS | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10013 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $87,771,537 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.NYGENOME.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2010 | FormationYr |
| Legal Domicile State | DE | LegalDomicileStateCd |
| Activity Or Mission | PROVIDING GLOBAL LEADERSHIP IN HUMAN GENOME RESEARCH AND ITS TRANSLATION INTO CLINICAL CARE. | ActivityOrMissionDesc |
| Voting Members Governing Body | 24 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 23 | VotingMembersIndependentCnt |
| Total Employee | 284 | TotalEmployeeCnt |
| Total Volunteers | 27 | TotalVolunteersCnt |
| Total Gross UBI | $816,492 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $81,695,780 | PYContributionsGrantsAmt |
| CY Contributions Grants | $75,537,348 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $9,712,534 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $4,904,919 | CYProgramServiceRevenueAmt |
| PY Investment Income | $191,646 | PYInvestmentIncomeAmt |
| CY Investment Income | $360,077 | CYInvestmentIncomeAmt |
| PY Other Revenue | $1,340,469 | PYOtherRevenueAmt |
| CY Other Revenue | $1,540,287 | CYOtherRevenueAmt |
| PY Total Revenue | $92,940,429 | PYTotalRevenueAmt |
| CY Total Revenue | $82,342,631 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $3,387,586 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $2,986,182 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $33,690,192 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $37,954,307 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $14,225 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $788 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $1,329,428 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $44,780,821 | PYOtherExpensesAmt |
| CY Other Expenses | $43,402,203 | CYOtherExpensesAmt |
| PY Total Expenses | $81,872,824 | PYTotalExpensesAmt |
| CY Total Expenses | $84,343,480 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $11,067,605 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$2,000,849 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $184,052,230 | TotalAssetsBOYAmt |
| Total Assets EOY | $166,954,755 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $138,136,156 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $123,038,215 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $45,916,074 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $43,916,540 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | OPERATE A STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $60,479,500 | ExpenseAmt |
| Grant | $2,986,182 | GrantAmt |
| Revenue | $4,233,105 | RevenueAmt |
| Desc | GENOME SEQUENCING: THE NEW YORK GENOME CENTER (NYGC) HAS ONE OF NEW YORK'S LARGEST AND MOST ADVANCED WHOLE GENOME SEQUENCING PROGRAMS, HAVING SEQUENCED OVER 106,885 WHOLE GENOME SAMPLES TO DATE. NYGC'S TWO STATE-OF-THE-ART ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS ARE EACH CAPABLE OF SEQUENCING 20,000 HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). SEE SCHEDULE O. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $7,674,355 | ExpenseAmt |
| Revenue | $671,814 | RevenueAmt |
| Desc | CLINICAL SEQUENCING: NYGC'S CLEP/CLIA CERTIFIED CLINICAL LABORATORY IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, MATERNAL CELL CONTAMINATION TESTING, AND ANEUPLOIDY SCREENING. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $68,153,855 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | Yes (1) | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | Yes (1) | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | Yes (1) | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 58 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 284 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | Yes (1) | UnrelatedBusIncmOverLimitInd |
| Form990 T Filed | Yes (1) | Form990TFiledInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 24 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 23 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (1) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | LA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ND | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | NANCY KONG | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 6469777154 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 AVENUE OF THE AMERICAS 7TH FL | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10013 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part VII | Yes (X) | InfoInScheduleOPartVIIInd |
Form990 Part VII Section A Form990PartVIISectionAGrp (40 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| TOM MANIATIS PHD | |||||||||
| SCIENTIFIC DIRECTOR & CEO | 40.00 | 0.00 | Yes (X) | Yes (X) | $675,040 | $0 | $0 | ||
| RUSSELL L CARSON MBA | |||||||||
| DIRECTOR & CHAIRMAN | 1.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| IVAN G SEIDENBERG MBA | |||||||||
| DIRECTOR & CO-CHAIR | 1.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| HERB PARDES MD | |||||||||
| DIR. & EXEC. VICE CHAIR (ENDED 4/24) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| BRUCE STILLMAN PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KATRINA ARMSTRONG MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| SELWYN M VICKERS MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DENNIS S CHARNEY MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DAFNA BAR-SAGI PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KEVIN J TRACEY MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KENNETH A DILL PHD | |||||||||
| DIRECTOR (ENDED 10/24) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| RICHARD P LIFTON MD PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| BARBARA ROSATI PHD | |||||||||
| DIRECTOR (STARTED 10/24) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ROBERT A HARRINGTON MD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ELI CASDIN | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| NICHOLAS DONOFRIO | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOSEPH E EDELMAN | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN B EHRENKRANZ | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ANTHONY B EVNIN PHD | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN P HAVENS | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| WESLIE R JANEWAY | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ALONDRA NELSON PHD | |||||||||
| DIRECTOR (STARTED 6/24) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| FRANK V SICA | |||||||||
| DIRECTOR & COMMITTEE CHAIR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DAVID N SPERGEL PHD | |||||||||
| DIRECTOR (STARTED 3/24) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JIM SIMONS PHD | |||||||||
| DIRECTOR (THROUGH 5/24) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| NANCY A THORNBERRY | |||||||||
| DIRECTOR | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| STEVEN J CORWIN MD | |||||||||
| DIRECTOR (STARTED 6/24) | 1.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ELIZABETH BROOKS O'BRIEN | |||||||||
| VP & GENERAL COUNSEL | 40.00 | 0.00 | Yes (X) | $468,516 | $0 | $46,016 | |||
| MARIA JOANTA | |||||||||
| CHIEF FINANCIAL OFFICER | 40.00 | 0.00 | Yes (X) | $385,785 | $0 | $51,441 | |||
| SARAH LESSER AVINS | |||||||||
| SVP, ADVANCEMENT & CHIEF D | 40.00 | 0.00 | $566,991 | $0 | $38,719 | Yes (X) | |||
| SOREN GERMER | |||||||||
| SVP, GENOME TECHNOLOGIES | 40.00 | 0.00 | $439,717 | $0 | $38,719 | Yes (X) | |||
| CAROL ASHE | |||||||||
| CHIEF BUSINESS OFFICER | 40.00 | 0.00 | $438,815 | $0 | $20,817 | Yes (X) | |||
| MICHAEL CHARLES ZODY | |||||||||
| SCIENTIFIC DIR, COMP BIOLO | 40.00 | 0.00 | $371,713 | $0 | $30,204 | Yes (X) | |||
| THOMAS LEHNER | |||||||||
| SCI DIR, NEURO DG (THROUGH 11/24) | 40.00 | 0.00 | $372,482 | $0 | $28,896 | Yes (X) | |||
| CHARLES GAGNON | |||||||||
| CHIEF INFORMATION OFFICER | 40.00 | 0.00 | $341,546 | $0 | $49,771 | Yes (X) | |||
| SHAILAJA GARGEYA | |||||||||
| SENIOR DIR, SOFTWARE ENGIN | 40.00 | 0.00 | $349,593 | $0 | $20,440 | Yes (X) | |||
| DAYNA M OSCHWALD | |||||||||
| CHIEF OF STAFF | 40.00 | 0.00 | $294,329 | $0 | $35,757 | Yes (X) | |||
| CHRISTOPHER PHIFER BLACK | |||||||||
| SR. DIR., RESEARCH COMP. | 40.00 | 0.00 | $263,806 | $0 | $45,444 | Yes (X) | |||
| AVINASH VIJAY ABHYANKAR | |||||||||
| DIRECTOR, CLINICAL BIOINFORM. | 40.00 | 0.00 | $259,321 | $0 | $41,952 | Yes (X) | |||
| CATHERINE E REEVES | |||||||||
| SR. DIR., SEQUENCING OPERATIONS | 40.00 | 0.00 | $241,489 | $0 | $36,532 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $5,469,143 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $484,708 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 103 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| DONNELLY MECHANICAL | |||||
| 96-59 222ND STREET | QUEENS | NY | 11429 | ENGINEERING SERVICES | $783,173 |
| GUARDIAN SERVICES INDUSTRIES INC | |||||
| 88005 EXPEDITE WAY | CHICAGO | IL | 60695 | CLEANING SERVICES | $399,966 |
| HOWSON & HOWSON LLP | |||||
| 325 SENTRY PARKWAY EAST | BLUE BELL | PA | 10422 | LEGAL SERVICES | $360,656 |
| SPENCERSTUART | |||||
| 353 N CLARK SUITE 2400 | CHICAGO | IL | 60654 | RECRUITING SERVICES | $224,340 |
| RSM US LLP | |||||
| 30 S 17TH ST SUITE 710 | PHILADELPHIA | PA | 19103 | CONSULTING SERVICES | $192,350 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 8 | CntrctRcvdGreaterThan100KCnt |
| Membership Dues | $2,435,000 | MembershipDuesAmt |
| Government Grants | $22,350,611 | GovernmentGrantsAmt |
| All Other Contributions | $50,751,737 | AllOtherContributionsAmt |
| Noncash Contributions | $310,488 | NoncashContributionsAmt |
| Total Contributions | $75,537,348 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt | Unrelated Business RevenueUnrelatedBusinessRevenueAmt |
|---|---|---|---|---|
| RESEARCH SEQUENCING | 541700 | $4,233,105 | $3,416,613 | $816,492 |
| CLINICAL SEQUENCING | 541700 | $671,814 | $671,814 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $4,904,919 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $100,871 | TotalRevenueColumnAmt |
| Exclusion | $100,871 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,683,278 | TotalRevenueColumnAmt |
| Exclusion | $1,683,278 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $4,563,829 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $5,428,906 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | -$865,077 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$865,077 | TotalRevenueColumnAmt |
| Exclusion | -$865,077 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $259,206 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $0 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $259,206 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $259,206 | TotalRevenueColumnAmt |
| Exclusion | $259,206 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | EDC LOAN RECOGNITION | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $722,086 | TotalRevenueColumnAmt |
| Exclusion | $722,086 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $722,086 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $82,342,631 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $4,088,427 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $816,492 | UnrelatedBusinessRevenueAmt |
| Exclusion | $1,900,364 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,668,307 | TotalAmt |
| Program Services | $2,668,307 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $317,875 | TotalAmt |
| Program Services | $317,875 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,365,188 | TotalAmt |
| Program Services | $1,956,771 | ProgramServicesAmt |
| Management And General | $1,802,707 | ManagementAndGeneralAmt |
| Fundraising | $605,710 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $25,603,693 | TotalAmt |
| Program Services | $19,579,840 | ProgramServicesAmt |
| Management And General | $5,629,217 | ManagementAndGeneralAmt |
| Fundraising | $394,636 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,526,695 | TotalAmt |
| Program Services | $1,130,593 | ProgramServicesAmt |
| Management And General | $349,052 | ManagementAndGeneralAmt |
| Fundraising | $47,050 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,096,722 | TotalAmt |
| Program Services | $2,456,982 | ProgramServicesAmt |
| Management And General | $613,345 | ManagementAndGeneralAmt |
| Fundraising | $26,395 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,362,009 | TotalAmt |
| Program Services | $2,683,383 | ProgramServicesAmt |
| Management And General | $616,019 | ManagementAndGeneralAmt |
| Fundraising | $62,607 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $455,423 | TotalAmt |
| Management And General | $455,423 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $141,144 | TotalAmt |
| Management And General | $141,144 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $60,000 | TotalAmt |
| Management And General | $60,000 | ManagementAndGeneralAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $788 | TotalAmt |
| Fundraising | $788 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,615,838 | TotalAmt |
| Program Services | $2,515,327 | ProgramServicesAmt |
| Management And General | $100,511 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $505,494 | TotalAmt |
| Program Services | $243,048 | ProgramServicesAmt |
| Management And General | $254,990 | ManagementAndGeneralAmt |
| Fundraising | $7,456 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,277,629 | TotalAmt |
| Program Services | $3,862,562 | ProgramServicesAmt |
| Management And General | $415,067 | ManagementAndGeneralAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $360,696 | TotalAmt |
| Program Services | $360,696 | ProgramServicesAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $13,258,040 | TotalAmt |
| Program Services | $10,612,675 | ProgramServicesAmt |
| Management And General | $2,532,183 | ManagementAndGeneralAmt |
| Fundraising | $113,182 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $457,045 | TotalAmt |
| Program Services | $406,595 | ProgramServicesAmt |
| Management And General | $48,880 | ManagementAndGeneralAmt |
| Fundraising | $1,570 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $107,362 | TotalAmt |
| Program Services | $80,790 | ProgramServicesAmt |
| Management And General | $24,311 | ManagementAndGeneralAmt |
| Fundraising | $2,261 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $290,077 | TotalAmt |
| Program Services | $195,569 | ProgramServicesAmt |
| Management And General | $92,887 | ManagementAndGeneralAmt |
| Fundraising | $1,621 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,565,363 | TotalAmt |
| Program Services | $6,207,285 | ProgramServicesAmt |
| Management And General | $319,367 | ManagementAndGeneralAmt |
| Fundraising | $38,711 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $797,641 | TotalAmt |
| Management And General | $797,641 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (3 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| DIRECT COST OF SEQUENCI | $9,324,415 | $9,324,415 | |
| RESEARCH | $3,376,498 | $3,376,498 | |
| RECRUITMENT | $332,450 | $19,202 | $313,248 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $477,088 | TotalAmt |
| Program Services | $155,442 | ProgramServicesAmt |
| Management And General | $294,205 | ManagementAndGeneralAmt |
| Fundraising | $27,441 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $84,343,480 | TotalAmt |
| Program Services | $68,153,855 | ProgramServicesAmt |
| Management And General | $14,860,197 | ManagementAndGeneralAmt |
| Fundraising | $1,329,428 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,326,778 | BOYAmt |
| EOY | $5,408,177 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,505,459 | BOYAmt |
| EOY | $4,402,079 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,649,498 | BOYAmt |
| EOY | $16,784,952 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,382,860 | BOYAmt |
| EOY | $7,076,051 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,607,153 | BOYAmt |
| EOY | $1,429,249 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,491,274 | BOYAmt |
| EOY | $2,478,585 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $146,378,144 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $102,893,087 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $46,071,277 | BOYAmt |
| EOY | $43,485,057 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $95,017,931 | BOYAmt |
| EOY | $85,890,605 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $184,052,230 | BOYAmt |
| EOY | $166,954,755 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,098,614 | BOYAmt |
| EOY | $5,863,554 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $14,803,697 | BOYAmt |
| EOY | $13,422,281 | EOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,660,000 | BOYAmt |
| EOY | $1,940,000 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $113,573,845 | BOYAmt |
| EOY | $101,812,380 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $138,136,156 | BOYAmt |
| EOY | $123,038,215 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,204,925 | BOYAmt |
| EOY | $14,697,417 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $25,711,149 | BOYAmt |
| EOY | $29,219,123 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $45,916,074 | BOYAmt |
| EOY | $43,916,540 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $184,052,230 | BOYAmt |
| EOY | $166,954,755 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$2,000,849 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $1,315 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $51,639,109 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $61,556,925 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $53,970,524 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $81,695,780 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $75,537,348 | CurrentTaxYearAmt |
| Total | $324,399,686 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $51,639,109 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $61,556,925 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $53,970,524 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $81,695,780 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $75,537,348 | CurrentTaxYearAmt |
| Total | $324,399,686 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $121,948,446 | SubstantialContributorsTotAmt |
| Public Support Total170 | $202,451,240 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $3,312,682 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $4,952,174 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $6,714,605 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $6,808,320 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $7,070,064 | CurrentTaxYearAmt |
| Total | $28,857,845 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $742,082 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $258,491 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $228,680 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $13,394 | CurrentTaxYearMinus1YearAmt |
| Total | $1,242,647 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $354,500,178 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $43,395,688 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.57110 | PublicSupportCY170Pct |
| Public Support PY170 | 0.60230 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | FormAndLineReferenceDesc |
| Explanation | OTHER INCOME - 2020 AMOUNT: $ 741,272. 2021 AMOUNT: $ 258,491. 2022 AMOUNT: $ 228,680. 2023 AMOUNT: $ 13,394. 2024 AMOUNT: $ 0. EVENT SPACE REVENUE - 2020 AMOUNT: $ 810. | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | 0 | VolunteersInd |
| Paid Staff Or Management | Yes (1) | PaidStaffOrManagementInd |
| Media Advertisements | 0 | MediaAdvertisementsInd |
| Mailings Members | 0 | MailingsMembersInd |
| Publications Or Broadcast | 0 | PublicationsOrBroadcastInd |
| Grants Other Organizations | 0 | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (1) | DirectContactLegislatorsInd |
| Direct Contact Legislators | $1,740 | DirectContactLegislatorsAmt |
| Rallies Demonstrations | 0 | RalliesDemonstrationsInd |
| Other Activities | Yes (1) | OtherActivitiesInd |
| Other Activities | $62,456 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $64,196 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | 0 | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-B, LINE 1: | FormAndLineReferenceDesc |
| Explanation | THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2024, NYGC ENGAGED PAID LEGISLATIVE CONSULTANTS TO REPRESENT ITS INTERESTS AT THE STATE LEVEL. ADDITIONALLY, FROM TIME TO TIME, NYGC STAFF MAY CONTACT MEMBERS OF THE STATE LEGISLATURE AND EXECUTIVE BRANCH TO ENCOURAGE THEIR SUPPORT FOR NYGC. SUCH CONTACT MAY INCLUDE MEETINGS AND CORRESPONDENCE WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH THESE ACTIVITIES IN 2024 WAS $1,740. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE ACADEMIC MEDICAL RESEARCH COMMUNITY. IN 2024, $2,456 OF THE DUES PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING. | ExplanationTxt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $3,481,000 | BeginningYearBalanceAmt |
| Contributions | $1,519,000 | ContributionsAmt |
| End Year Balance | $5,000,000 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributions | $3,481,000 | ContributionsAmt |
| End Year Balance | $3,481,000 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 1.00000 | BoardDesignatedBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $71,396,055 | OtherCostOrOtherBasisAmt |
| Depreciation | $38,077,082 | DepreciationAmt |
| Book Value | $33,318,973 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $70,433,221 | OtherCostOrOtherBasisAmt |
| Depreciation | $61,453,632 | DepreciationAmt |
| Book Value | $8,979,589 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $4,548,868 | OtherCostOrOtherBasisAmt |
| Depreciation | $3,362,373 | DepreciationAmt |
| Book Value | $1,186,495 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $43,485,057 | TotalBookValueLandBuildingsAmt |
Other Assets Org OtherAssetsOrgGrp (3 entries)
| DescDesc | Book ValueBookValueAmt |
|---|---|
| SECURITY DEPOSITS | $5,561,947 |
| DEFERRED COMPENSATION RETIREMENT PLAN | $265,805 |
| OPERATING RIGHT-OF-USE-ASSET | $80,062,853 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Other Assets | $85,890,605 | TotalBookValueOtherAssetsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| RIGHT-OF-USE-LIABILITY | $100,610,678 |
| FINANCING LEASE OBLIGATIONS | $1,201,702 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $101,812,380 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $88,058,852 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $1,315 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $286,000 | DonatedServicesAndUseFcltsAmt |
| Revenue Not Reported | $287,315 | RevenueNotReportedAmt |
| Revenue Subtotal | $87,771,537 | RevenueSubtotalAmt |
| Other Revenues Not Included | -$5,428,906 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | -$5,428,906 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $82,342,631 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $90,058,386 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $286,000 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $5,428,906 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $5,714,906 | ExpensesNotReportedAmt |
| Expenses Subtotal | $84,343,480 | ExpensesSubtotalAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $84,343,480 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART V, LINE 4: | THE THOMAS MANIATIS CHAIR FOR EXCELLENCE AND INNOVATION IN GENOMIC SCIENCE FUND WAS ESTABLISHED TO RECOGNIZE AND HONOR THE INTEGRAL ROLE PLAYED BY THOMAS MANIATIS, PH.D., IN MAKING THE NEW YORK GENOME CENTER A LEADER IN THE FURTHERANCE OF GENOMIC RESEARCH. A DESIGNATED PORTION, APPROXIMATELY 5% OF THE FUND'S EARNINGS ANNUALLY WILL BE MADE AVAILABLE FOR GENERAL EXPENDITURE. THE BOARD OF DIRECTORS HAS DISCRETION TO MAKE ADDITIONAL FUNDS AVAILABLE TO SUPPORT THE ESSENTIAL NEEDS OF THE ORGANIZATION. |
| PART X, LINE 2: | NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2024 AND 2023. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | RECLASS OF DIRECT RENTAL EXPENSE -5,428,906. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | RECLASS OF DIRECT RENTAL EXPENSE 5,428,906. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (5 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND AND GREENLAND) | 0 | 2 | PROGRAM SERVICES | RESEARCH | $127,064 |
| NORTH AMERICA | 0 | 1 | PROGRAM SERVICES | RESEARCH | $67,729 |
| AFRICA | 0 | 0 | PROGRAM SERVICES | RESEARCH | $33,360 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | GRANTMAKING | $150,110 | |||
| NORTH AMERICA | GRANTMAKING | $167,765 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 3 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 3 | TotalEmployeeCnt |
| Subtotal Spent | $546,028 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $546,028 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (2 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND AND GREENLAND) | RESEARCH SUBAWARD | $114,023 | WIRE | $0 |
| NORTH AMERICA | RESEARCH SUBAWARD | $36,087 | WIRE | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 1 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Foreign Individuals Grants ForeignIndividualsGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Type Of Assistance | RESEARCH | TypeOfAssistanceTxt |
| Region | NORTH AMERICA | RegionTxt |
| Recipient | 1 | RecipientCnt |
| Cash Grant | $167,765 | CashGrantAmt |
| Manner Of Cash Disbursement | WIRE | MannerOfCashDisbursementTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. |
| PART I, LINE 3: | THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (14 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|---|
| COLUMBIA UNIVERSITY | ||||||||
| 615 WEST 131ST STREET MC841 | NEW YORK | NY | 100277922 | 135598093 | 501(C)(3) | $375,710 | $0 | RESEARCH SUBAWARD |
| NEW YORK UNIVERSITY | ||||||||
| 70 WASHINGTON SQUARE SOUTH | NEW YORK | NY | 10012 | 135562308 | 501(C)(3) | $38,422 | $0 | RESEARCH SUBAWARD |
| ROCKEFELLER UNIVERSITY | ||||||||
| 1230 YORK AVENUE | NEW YORK | NY | 10065 | 131624158 | 501(C)(3) | $93,797 | $0 | RESEARCH SUBAWARD |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | ||||||||
| 1 GUSTAVE L LEVY PLACE | NEW YORK | NY | 10029 | 136171197 | 501(C)(3) | $143,729 | $0 | RESEARCH SUBAWARD |
| NYU GROSSMAN SCHOOL OF MEDICINE | ||||||||
| 550 FIRST AVENUE | NEW YORK | NY | 10016 | 135562309 | 501(C)(3) | $205,910 | $0 | RESEARCH SUBAWARD |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | ||||||||
| 1275 YORK AVENUE | NEW YORK | NY | 10065 | 131924236 | 501(C)(3) | $279,421 | $0 | RESEARCH SUBAWARD |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| 3400 N CHARLES STREET | BALTIMORE | MD | 21218 | 520595110 | 501(C)(3) | $354,063 | $0 | RESEARCH SUBAWARD |
| COLD SPRING HARBOR LABORATORY | ||||||||
| 1 BUNGTOWN ROAD | COLD SPRING HARBOR | NY | 11724 | 112013303 | 501(C)(3) | $200,000 | $0 | RESEARCH SUBAWARD |
| YALE UNIVERSITY | ||||||||
| 135 COLLEGE STREET | NEW HAVEN | CT | 06510 | 060646973 | 501(C)(3) | $20,951 | $0 | RESEARCH SUBAWARD |
| MOREHOUSE SCHOOL OF MEDICINE INC | ||||||||
| 720 WESTVIEW DRIVE SW | ATLANTA | GA | 303101458 | 581438873 | 501(C)(3) | $95,176 | $0 | RESEARCH SUBAWARD |
| THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | ||||||||
| 350 COMMUNITY DRIVE | MANHASSET | NY | 11030 | 112673595 | 501(C)(3) | $79,582 | $0 | RESEARCH SUBAWARD |
| WEILL CORNELL MEDICAL COLLEGE | ||||||||
| 1300 YORK AVENUE | NEW YORK | NY | 10065 | 150532082 | 501(C)(3) | $111,815 | $0 | RESEARCH SUBAWARD |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | ||||||||
| 1111 FRANKLIN STREET | OAKLAND | CA | 94607 | 943067788 | 501(C)(3) | $37,951 | $0 | RESEARCH SUBAWARD |
| RUTGERS THE STATE UNIVERSITY | ||||||||
| 33 KNIGHTSBRIDGE ROAD C281 | PISCATAWAY | NJ | 08854 | 226001086 | 501(C)(3) | $65,864 | $0 | RESEARCH SUBAWARD |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 14 | Total501c3OrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOM MANIATIS PHD | ||||||||||||||
| SCIENTIFIC DIRECTOR & CEO | $675,040 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $675,040 | $0 | $0 | $0 |
| SARAH LESSER AVINS | ||||||||||||||
| SVP, ADVANCEMENT & CHIEF D | $566,991 | $0 | $0 | $0 | $0 | $0 | $20,700 | $0 | $18,019 | $0 | $605,710 | $0 | $0 | $0 |
| ELIZABETH BROOKS O'BRIEN | ||||||||||||||
| VP & GENERAL COUNSEL | $468,516 | $0 | $0 | $0 | $0 | $0 | $20,700 | $0 | $25,316 | $0 | $514,532 | $0 | $0 | $0 |
| SOREN GERMER | ||||||||||||||
| SVP, GENOME TECHNOLOGIES | $439,717 | $0 | $0 | $0 | $0 | $0 | $20,700 | $0 | $18,019 | $0 | $478,436 | $0 | $0 | $0 |
| CAROL ASHE | ||||||||||||||
| CHIEF BUSINESS OFFICER | $438,815 | $0 | $0 | $0 | $0 | $0 | $20,700 | $0 | $117 | $0 | $459,632 | $0 | $0 | $0 |
| MARIA JOANTA | ||||||||||||||
| CHIEF FINANCIAL OFFICER | $341,190 | $0 | $0 | $0 | $44,595 | $0 | $20,700 | $0 | $30,741 | $0 | $437,226 | $0 | $0 | $0 |
| MICHAEL CHARLES ZODY | ||||||||||||||
| SCIENTIFIC DIR, COMP BIOLO | $371,713 | $0 | $0 | $0 | $0 | $0 | $20,700 | $0 | $9,504 | $0 | $401,917 | $0 | $0 | $0 |
| THOMAS LEHNER | ||||||||||||||
| SCI DIR, NEURO DG (THROUGH 11/24) | $343,152 | $0 | $0 | $0 | $29,330 | $0 | $13,396 | $0 | $15,500 | $0 | $401,378 | $0 | $0 | $0 |
| CHARLES GAGNON | ||||||||||||||
| CHIEF INFORMATION OFFICER | $341,546 | $0 | $0 | $0 | $0 | $0 | $17,590 | $0 | $32,181 | $0 | $391,317 | $0 | $0 | $0 |
| SHAILAJA GARGEYA | ||||||||||||||
| SENIOR DIR, SOFTWARE ENGIN | $329,545 | $0 | $950 | $0 | $19,098 | $0 | $20,323 | $0 | $117 | $0 | $370,033 | $0 | $0 | $0 |
| DAYNA M OSCHWALD | ||||||||||||||
| CHIEF OF STAFF | $294,329 | $0 | $0 | $0 | $0 | $0 | $17,813 | $0 | $17,944 | $0 | $330,086 | $0 | $0 | $0 |
| CHRISTOPHER PHIFER BLACK | ||||||||||||||
| SR. DIR., RESEARCH COMP. | $263,806 | $0 | $0 | $0 | $0 | $0 | $16,263 | $0 | $29,181 | $0 | $309,250 | $0 | $0 | $0 |
| AVINASH VIJAY ABHYANKAR | ||||||||||||||
| DIRECTOR, CLINICAL BIOINFORM. | $259,321 | $0 | $0 | $0 | $0 | $0 | $15,947 | $0 | $26,005 | $0 | $301,273 | $0 | $0 | $0 |
| CATHERINE E REEVES | ||||||||||||||
| SR. DIR., SEQUENCING OPERATIONS | $241,489 | $0 | $0 | $0 | $0 | $0 | $15,413 | $0 | $21,119 | $0 | $278,021 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 3 | IN 2024, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION, AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED THE REMAINING 20% OF HIS TIME TO HIS OWN RESEARCH LABORATORY AT THE UNRELATED ENTITY, WHERE HE MAINTAINED A LABORATORY AND CONDUCTED INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN 2024, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO WAS REASONABLE. |
| PART I, LINE 7 | CERTAIN INDIVIDUALS LISTED ON SCHEDULE J, PART II RECEIVED DISCRETIONARY BONUSES IN 2024. |
Schedule L IRS990ScheduleL
Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp
Name Of Interested NameOfInterested
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | SILAS MANIATIS | PersonNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Relationship Description | FAMILY MEMBER | RelationshipDescriptionTxt |
| Transaction | $191,812 | TransactionAmt |
| Transaction | SALARY+BEN | TransactionDesc |
| Sharing Of Revenues | 0 | SharingOfRevenuesInd |
Schedule M IRS990ScheduleM
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | RESEARCH SUPPLIES | Desc |
| Contribution | 103 | ContributionCnt |
| Noncash Contributions Rpt F990 | $310,488 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B) | FormAndLineReferenceDesc |
| Explanation | THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF ITEMS CONTRIBUTED. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (11 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART I, LINE 1 & PART III, LINE 1: | THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT NON-PROFIT SCIENTIFIC RESEARCH INSTITUTION DEDICATED TO COLLABORATIVE GENOMIC RESEARCH. NYGC'S MISSION IS TO ADVANCE GENOMIC SCIENCE TO DRIVE NOVEL BIOMEDICAL DISCOVERIES AND TRANSFORM PATIENT CARE THROUGH PRECISION MEDICINE. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL GENOMIC METHODS AND DISEASE-FOCUSED RESEARCH TO FURTHER THE UNDERSTANDING OF THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE, AND NEUROPSYCHIATRIC DISEASE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS, PHD, INCLUDES ASSOCIATE AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE CENTER BRINGS TOGETHER OUTSTANDING THOUGHT LEADERS FROM TEN FOUNDING & THREE ASSOCIATE MEMBER INSTITUTIONS, AS WELL AS 95 AFFILIATE SCIENTIFIC MEMBERS, TO ENGAGE IN COLLABORATIVE RESEARCH. CONVENING TALENT AND EXPERTISE FROM MULTIPLE TOP-TIER SCIENTIFIC AND MEDICAL INSTITUTIONS IN THE NEW YORK AREA AND BEYOND, NYGC HAS CREATED A HIGHLY COLLABORATIVE SCIENTIFIC ECOSYSTEM AND COMMUNITY RESOURCE THAT IS MORE THAN THE SUM OF ITS PARTS. NYGC ALSO PROVIDES RESEARCHERS WITH ACCESS TO STATE-OF-THE-ART GENOMIC INFRASTRUCTURE (E.G., A HIGH-PERFORMANCE COMPUTING INFRASTRUCTURE, SOFTWARE, AND NEXT-GENERATION SEQUENCING INSTRUMENTS), AS WELL AS TECHNOLOGY INNOVATION KNOW-HOW AND EXPERTISE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITIES IN NEW YORK CITY, ACROSS THE UNITED STATES, AND AROUND THE WORLD, FOSTERING INNOVATION AND KNOWLEDGE EXCHANGE; (II) RECRUITING AND RETAINING DIVERSE, WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH, AND MEDICAL INSTITUTIONS, AS WELL AS THE BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRY, TO ADVANCE NYGC'S SCIENTIFIC RESEARCH MISSION; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED ON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED BY NYGC FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) IMPROVING HUMAN HEALTH THROUGH GENOMIC RESEARCH THAT DRIVES NOVEL BIOMEDICAL DISCOVERIES; (VI) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH, AND TECHNOLOGY DEVELOPMENT COMMUNITIES; (VII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL, WHERE EVERY INDIVIDUAL FEELS VALUED AND RESPECTED, REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, RELIGION, OR VETERAN STATUS, AND (VIII) CARRYING OUT ACTIVITIES ANCILLARY TO THESE OBJECTIVES. |
| FORM 990, PART III, LINE 4A & LINE 4B | NYGC IS COMMITTED TO ADVANCING GENOMIC SCIENCE TO DRIVE NOVEL BIOMEDICAL DISCOVERIES AND TRANSFORM PATIENT CARE THROUGH PRECISION MEDICINE. RESEARCH AND FACULTY NYGC MAINTAINS A STRONG COMMITMENT TO RECRUITING OUTSTANDING FACULTY WITH BROAD EXPERTISE IN DISEASE GENOMICS, COMPUTATIONAL AND MACHINE LEARNING APPROACHES, ENGINEERING, AND GENOMIC TECHNOLOGIES. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. EACH FACULTY MEMBER HAS BUILT A ROBUST RESEARCH PROGRAM AND HOLDS A JOINT TENURE-TRACK APPOINTMENT AT ONE OF OUR PARTNER INSTITUTIONS. NYGC ALSO HAS A DISTINGUISHED GROUP OF SENIOR ASSOCIATE FACULTY, AFFILIATE MEMBERS, AND A SCIENTIFIC ADVISORY BOARD (SAB) COMPRISED OF WORLD-LEADERS IN GENOMICS AND WHO BRING INVALUABLE SCIENTIFIC LEADERSHIP AND MENTORSHIP TO THE CENTER. OUR SENIOR LEADERSHIP TEAM, TOGETHER WITH THE EXTENSIVE EXPERIENCE AND GUIDANCE OF OUR SENIOR FACULTY AND SCIENTIFIC ADVISORY BOARD, EMPOWERS THE NEXT GENERATION OF GENOMIC RESEARCHERS TO PURSUE GROUNDBREAKING DISCOVERIES IN BIOMEDICAL RESEARCH, DRIVING ADVANCEMENTS THAT CAN TRANSFORM HEALTHCARE AND IMPROVE PATIENT OUTCOMES. IN 2024, NYGC SCIENTISTS PUBLISHED 78 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS, ESTABLISHING NEW INSIGHTS INTO THE CAUSES AND MECHANISMS OF DISEASE, INNOVATIVE NEW GENOMIC TECHNOLOGIES, AND NOVEL COMPUTATIONAL APPROACHES SHARED WIDELY WITH THE SCIENTIFIC COMMUNITY TO HELP ADVANCE PRECISION MEDICINE. TWO OF NYGC'S CORE FACULTY MEMBERS, RAHUL SATIJA, PHD, AND NEVILLE SANJANA, PHD, WERE ONCE AGAIN NAMED AMONG THE WORLD'S MOST CITED RESEARCHERS ON CLARIVATE ANALYTICS' 2024 HIGHLY CITED RESEARCHERS LIST FOR THE SIXTH CONSECUTIVE YEAR, A TESTAMENT TO THEIR IMPACTFUL CONTRIBUTIONS AND INFLUENCE IN THEIR RESPECTIVE FIELDS OF STUDY. THIS ANNUAL LIST GATHERS THOSE IN THE FIELD WHO DEMONSTRATED SIGNIFICANT AND BROAD INFLUENCE REFLECTED IN THEIR PUBLICATIONS OF MULTIPLE HIGHLY CITED PAPERS OVER THE LAST DECADE. THE HIGHLY CITED PAPERS RANK IN THE TOP 1% BY CITATION FOR A FIELD OR FIELDS AND PUBLICATION YEAR IN THE WEB OF SCIENCE. IN 2024, NYGC EXPANDED ITS COMMITMENT TO SCIENTIFIC TRAINING WITH THE LAUNCH OF ITS EARLY CAREER DEVELOPMENT PROGRAM FOR POST-BACCALAUREATES. THIS PROGRAM WELCOMED ITS FIRST COHORT OF ASPIRING RESEARCHERS WITH THE OPPORTUNITY TO GAIN HANDS-ON RESEARCH EXPERIENCE IN GENOMICS, COMPUTATIONAL BIOLOGY, TECHNOLOGY INNOVATION, AND CLINICAL GENETIC TESTING. NYGC HAS CONTINUED TO MAKE SIGNIFICANT PROGRESS IN ITS CORE RESEARCH AREAS. NOTEWORTHY EXAMPLES OF THIS PROGRESS INCLUDE: CANCER: NYGC'S SIGNATURE POLYETHNIC-1000 (P-1000) IS A MULTI-INSTITUTIONAL COLLABORATIVE EFFORT LED BY DRS. HAROLD VARMUS AND CHARLES SAWYERS, NYGC'S CANCER GROUP, AND LEADERS FROM ACROSS NEW YORK CITY'S CANCER RESEARCH COMMUNITY, LEVERAGING THE CITY'S EXTRAORDINARY DIVERSITY TO ADVANCE CANCER GENOMICS AND ITS APPLICATION IN CLINICAL CARE. DESIGNED TO DEMOCRATIZE CANCER GENOMICS THROUGH WHOLE-GENOME SEQUENCING, BIOINFORMATIC ANALYSIS, CLINICAL RESEARCH, AND COMMUNITY OUTREACH, P-1000 HAS CREATED A POWERFUL PLATFORM FOR UNDERSTANDING HOW DIFFERENT GENETIC BACKGROUNDS INFLUENCE CANCER. THIS WIDELY RECOGNIZED FRAMEWORK LAID THE FOUNDATION FOR TEAM SAMBAI, RECIPIENT OF THE PRESTIGIOUS CANCER GRAND CHALLENGE (CGC) AWARD. LED BY DR. MELISSA DAVIS, NYGC ASSOCIATE FACULTY MEMBER; DIRECTOR, INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE, MOREHOUSE SCHOOL OF MEDICINE; SCIENTIFIC DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF BREAST CANCER SUBTYPES; DIRECTOR OF HEALTH EQUITY, ENGLANDER INSTITUTE OF PRECISION MEDICINE; AND ASSOCIATE PROFESSOR OF CELL AND DEVELOPMENTAL BIOLOGY, WEILL CORNELL MEDICINE, TEAM SAMBAI (SOCIETAL, ANCESTRY, MOLECULAR, AND BIOLOGICAL ANALYSES OF INEQUALITIES) UNITES EXPERTS IN CANCER GENOMICS, IMMUNOLOGY, EPIDEMIOLOGY, EXPOSOMICS, AND PATIENT ADVOCACY. SELECTED AS ONE OF ONLY FIVE INTERNATIONAL RESEARCH TEAMS, AND THE SOLE GROUP CHOSEN FROM A HIGHLY COMPETITIVE GLOBAL POOL FOCUSED ON CANCER INEQUITIES - ONE OF THE NINE CGC-IDENTIFIED TOUGHEST CHALLENGES IN CANCER IN 2024 - TEAM SAMBAI WILL RECEIVE UP TO $25 MILLION IN FUNDING TO CARRY THIS VITAL WORK FORWARD. NEURODEGENERATIVE DISEASE: THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), AT NYGC, LED BY NYGC CORE FACULTY MEMBER, HEMALI PHATNANI, PHD, HAS ESTABLISHED A GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONSORTIUM, CONSISTING OF 46 MEMBER INSTITUTIONS WORLDWIDE. THE CGND HAS ALSO CONTRIBUTED TO ALS RESEARCH WITH THE DEVELOPMENT OF GENOMIC TECHNOLOGIES FOR THE STUDY OF RNA, SINGLE CELL AND SPATIALLY-RESOLVED TRANSCRIPTOMICS. NYGC LEVERAGES THE SUCCESS OF THE CGND'S FOCUS ON ALS RESEARCH TO EXTEND THIS WORK ACROSS A WIDER RANGE OF NEURODEGENERATIVE DISEASES THAT SHARE COMMON PATHWAYS WITH ALS; SUCH DISEASES INCLUDE VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA (FTD), PARKINSON'S DISEASE, AND HUNTINGTON'S DISEASE. DR. HEMALI PHATNANI'S LAB AT NYGC, IN COLLABORATION WITH THE ALS CONSORTIUM, MADE SIGNIFICANT STRIDES IN ALS RESEARCH IN 2024 BY IDENTIFYING THREE DISTINCT MOLECULAR SUBTYPES OF THE DISEASE. THESE MOLECULAR SUBTYPES WERE FOUND TO CORRELATE WITH SPECIFIC PATTERNS OF GENE EXPRESSION, AND EACH HAD DISTINCT CLINICAL FEATURES. UNDERSTANDING THESE SUBTYPES MAY OFFER NEW AVENUES FOR TARGETED TREATMENTS AND IMPROVING THE PRECISION OF ALS THERAPIES. NEUROPSYCHIATRIC DISEASE: THE NYGC IS LEADING A NEW PROJECT THAT WILL DEVELOP NOVEL ARTIFICIAL INTELLIGENCE FRAMEWORKS AND ADVANCED COMPUTATIONAL INFRASTRUCTURE TO EFFECTIVELY HARNESS THE WEALTH OF INFORMATION CONTAINED IN MEDICAL RECORDS AND GENOMIC DATA, AND DEPLOY THAT KNOWLEDGE IN A NOVEL FRAMEWORK FOR PRECISION PSYCHIATRY. THIS FRAMEWORK WILL BE INTEGRATED, IN COLLABORATION WITH MICHAEL ZODY, PHD, NYGC SCIENTIFIC DIRECTOR OF COMPUTATIONAL BIOLOGY, AND CHARLES GAGNON, NYGC'S CHIEF INFORMATION OFFICER, INTO A DATA COMMONS ESTABLISHED TO DISSEMINATE DATA FROM THE CENTER'S GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) INITIATIVE, A TRANSLATIONAL PLATFORM FOR PRECISION PSYCHIATRY DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE-BASED MENTAL HEALTH CARE, WITH A STRONG EMPHASIS ON DATA SECURITY AND PATIENT PRIVACY. COLLECTIVELY, THESE EFFORTS PROMISE TO SIGNIFICANTLY ADVANCE PRECISION PSYCHIATRY BY ENABLING MORE ACCURATE DISEASE-GENE ASSOCIATIONS AND FACILITATING DEMOCRATIZED DATA SHARING, ALL WHILE UPHOLDING HIGH STANDARDS OF DATA PRIVACY. IN COLLABORATION WITH RESEARCHERS AT COLUMBIA UNIVERSITY IRVING MEDICAL CENTER, ZUCKER HILLSIDE HOSPITAL OF NORTHWELL HEALTH, NEW YORK UNIVERSITY, AND THE UNIVERSITY OF CHICAGO, NYGC WAS AWARDED A GRANT FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH TO ADVANCE PRECISION PSYCHIATRY USING ARTIFICIAL INTELLIGENCE. THE COPPER (CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM ELECTRONIC HEALTH RECORDS) PROJECT WILL INTEGRATE ELECTRONIC HEALTH RECORDS, DETAILED PATIENT INFORMATION, AND GENETIC DATA TO DEVELOP PREDICTIVE MODELS FOR TREATMENT RESPONSE, ILLNESS SEVERITY, AND RISK OF COMORBIDITIES IN INDIVIDUALS WITH PSYCHOSIS. LED BY MICHAEL ZODY, PHD, NYGC'S SCIENTIFIC DIRECTOR OF COMPUTATIONAL BIOLOGY, AND VAIDEHI JOBANPUTRA, PHD, FACMG, NYGC'S CHIEF DIAGNOSTICS OFFICER, THE PROJECT WILL SEQUENCE 10,000 PATIENTS WITH SCHIZOPHRENIA TO IDENTIFY RARE, STRUCTURAL, AND COMMON VARIANTS AND INVESTIGATE THEIR ROLE IN CLINICAL PREDICTIONS. COPPER AIMS TO ENABLE EARLY INTERVENTION AND SUPPORT, PAVING THE WAY FOR PRECISION PSYCHIATRY TAILORED TO INDIVIDUAL NEEDS. |
| FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) | GENOMIC TECHNOLOGY: THIS YEAR, THE NYGC TECHNOLOGY INNOVATION LAB HAS FOCUSED SIGNIFICANT EFFORTS ON ADVANCING SPATIAL GENOMICS AND MOLECULAR PROFILING TECHNOLOGIES. THROUGH INNOVATIVE PROJECTS LIKE MICROST, SPATIAL CUT&TAG, AND THE DEVELOPMENT OF THE CSPLOTCH ALGORITHM, THE TEAM IS DELIVERING TOOLS THAT ENHANCE OUR UNDERSTANDING OF GENE EXPRESSION, CELLULAR COMPOSITION, AND TISSUE-SPECIFIC GENE REGULATION. THESE PROJECTS ARE NOT ONLY EXPANDING THE AVAILABLE RESEARCH TOOLKIT AND CAPABILITIES IN THE FIELD, BUT ALSO REVEALING NEW INSIGHTS INTO THE MOLECULAR MECHANISMS UNDERLYING COMPLEX BIOLOGICAL PROCESSES, AGING, AND DISEASE - INSIGHTS THAT MAY PAVE THE WAY FOR FUTURE THERAPEUTIC BREAKTHROUGHS. THE NYGC HAS BUILT AN IMPRESSIVE GENOMIC TECHNOLOGY AND SEQUENCING INFRASTRUCTURE, ENABLING HIGH-THROUGHPUT NEXT-GENERATION SEQUENCING WITH ROBUST ANALYTICS AND BROAD ACCESS TO CUTTING-EDGE TECHNOLOGIES TO THE NEW YORK RESEARCH COMMUNITY. THE NYGC PRODUCTION SEQUENCING LAB HAS BEEN GENERATING SEQUENCING DATA FOR A LARGE NUMBER OF PROJECTS AND A DIVERSE SET OF INVESTIGATORS FROM THROUGHOUT THE NEW YORK CITY COMMUNITY AND BEYOND, INCLUDING FOR MAJOR NIH GRANTS AND FOR THE BRAIN INITIATIVE CELL ATLAS NETWORK (BICAN), PRIMARILY IN COLLABORATION WITH THE ALLEN INSTITUTE IN SEATTLE. THE LAB HAS SEQUENCED NEARLY 200 ILLUMINA FLOW CELLS (NEARLY 3 TRILLION SEQUENCING READS), GENERATING LARGE SCALE SINGLE CELL AND MULTIOMIC DATA FOR THE ATLAS. THE CENTER REMAINS AT THE FOREFRONT OF HIGH-QUALITY SEQUENCING AT SCALE THROUGH EARLY AND STRATEGIC INVESTMENT IN THE LATEST TOOLS AND TECHNOLOGIES. CLINICAL LABORATORY: NYGC HOUSES A STATE-OF-THE-ART CLINICAL DIAGNOSTIC LABORATORY THAT UTILIZES NEXT-GENERATION SEQUENCING TECHNOLOGY TO PERFORM ADVANCED TESTS IN GENETICS AND ONCOLOGY. THIS LAB IS FOUNDATIONAL TO NYGC'S ABILITY TO DELIVER RAPID, HIGH-QUALITY CLINICAL GENOMIC SERVICES THAT ARE DIRECTLY SHAPING PATIENT CARE. ONE OF NYGC'S FLAGSHIP INITIATIVES IS THE WOMEN'S GENETICS CENTER (WGC), LAUNCHED IN PARTNERSHIP WITH NEW YORK-PRESBYTERIAN HOSPITAL AND COLUMBIA UNIVERSITY IRVING MEDICAL CENTER. THIS COLLABORATION IS DEDICATED TO CHANGING WOMEN'S HEALTHCARE THROUGH THE CLINICAL APPLICATION OF GENOME SEQUENCING (GS). THE WGC IS DEVELOPING AFFORDABLE, ROUTINE GS-BASED TESTS FOR WOMEN SEEKING GENETIC CONSULTATION FOR PREGNANCY PLANNING, FETAL ANOMALIES, AND PRENATAL GENETIC TESTING. THE GOAL IS TO EVENTUALLY REPLACE TRADITIONAL TESTS, SUCH AS KARYOTYPING, CHROMOSOMAL MICROARRAYS, AND PANEL OR EXOME SEQUENCING, WITH MORE COMPREHENSIVE, COST-EFFECTIVE GS SOLUTIONS. COMMUNITY: IN SUPPORT OF NYGC'S VISION AND VALUES, NYGC IS COMMITTED TO FOSTERING COMMUNITY AND A CULTURE OF BELONGING, SHARED PURPOSE, AND MUTUAL RESPECT. THE ORGANIZATION HAS BEEN WORKING TO HELP EMPLOYEES FEEL CONNECTED TO THEIR WORK AND THE CENTER'S CORE VALUES, WHILE BUILDING A STRONG SENSE OF COMMUNITY. OUR GOAL IS TO ENSURE THAT EVERY COMMUNITY MEMBER FEELS REPRESENTED, RESPECTED, SUPPORTED, AND TREATED WITH DIGNITY, WHILE CELEBRATING THEIR UNIQUE BACKGROUNDS, TALENTS, AND PERSPECTIVES. |
| FORM 990, PART VI, SECTION A, LINE 2 | NYGC BOARD MEMBERS ELI CASDIN, ANTHONY EVNIN, THOMAS MANIATIS, AND NANCY THORNBERRY HAVE A BUSINESS RELATIONSHIP, EITHER DIRECTLY OR INDIRECTLY, THROUGH KALLYOPE, INC., A BIOTECHNOLOGY COMPANY DEVELOPING ORAL THERAPEUTICS AGAINST METABOLIC, NEUROLOGICAL, AND GASTROINTESTINAL DISEASES. NYGC HAS NOT CONDUCTED ANY BUSINESS WITH KALLYOPE, INC. |
| FORM 990, PART VI, SECTION A, LINE 6 | ORGANIZATION MEMBERS AS OF DECEMBER 31, 2024, THE CENTER HAD A TOTAL OF 13 MEMBERS, CONSISTING OF TEN INSTITUTIONAL FOUNDING MEMBERS AND THREE ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL, AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) MEMORIAL SLOAN-KETTERING CANCER CENTER, (4) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (5) NEW YORK-PRESBYTERIAN HOSPITAL, (6) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (7) NORTHWELL HEALTH, (8) ROCKEFELLER UNIVERSITY (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, AND (10) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, AND (3) HACKENSACK MERIDIAN HEALTH. |
| FORM 990, PART VI, SECTION A, LINE 7A | ORGANIZATION MEMBERS - DECISION MAKING EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR/CEO AND INDEPENDENT DIRECTORS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS, AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 REVIEW THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER, GENERAL COUNSEL, AND THE SCIENTIFIC DIRECTOR & CEO, REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. PRIOR TO FILING, MANAGEMENT ALSO PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION B, LINE 12C | CONFLICT OF INTEREST POLICY & REVIEW NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION REVIEW AND APPROVAL FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2024, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE. THE COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET AT A COMMITTEE MEETING HELD IN JANUARY 2024 AND APPROVED THE 2024 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. THE SENIOR MANAGEMENT TEAM DID NOT RECEIVE MERIT INCREASES IN 2024. |
| FORM 990, PART VI, SECTION C, LINE 19 | DOCUMENT AVAILABILITY NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART VII, SECTION A | IN 2024, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVE AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINED A LABORATORY AND CONDUCTED INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. |